Chiness Journal of Clinical Medicine

Recommendations for clinical diagnosis and treatment of immune checkpoint inhibitors-associated myocarditis

Received:October 13, 2022 Revised:December 06, 2022 Click here to download the full text

Citation of this paper:WANG Yan,CHEN Hui-yong,LIN Jin-yi,CHEN Jia-hui,ZHOU Yu-hong,ZHANG Ying-mei,ZHANG Hong-wei,ZHU Wei,HU Jie,ZHAO Gang,YANG Xiang-dong,DU Shi-suo,LI Xiao-yu,SHI Guo-ming,CUI Jie,WU Wei,LI Jing,ZHANG Chi,WANG Cong,LIU Rong-le,LI Zheng,WANG Chun-hui,CHENG Lei-lei,GE Jun-bo.Recommendations for clinical diagnosis and treatment of immune checkpoint inhibitors-associated myocarditis[J].Chinese Journal of Clinical Medicine,2023,30(2):368-391

Hits: 2923

Download times: 716

Author Name	Affiliation	E-mail
WANG Yan	Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
CHEN Hui-yong	Department of Rheumatology and Immunology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
LIN Jin-yi	Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China National Clinical Study Center for Radiology and Therapy, Shanghai 200032, China Shanghai Institute of Cardiovascular Diseases, Shanghai 200032, China
CHEN Jia-hui	Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China National Clinical Study Center for Radiology and Therapy, Shanghai 200032, China Shanghai Institute of Cardiovascular Diseases, Shanghai 200032, China
ZHOU Yu-hong	Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
ZHANG Ying-mei	Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China National Clinical Study Center for Radiology and Therapy, Shanghai 200032, China Shanghai Institute of Cardiovascular Diseases, Shanghai 200032, China
ZHANG Hong-wei	Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China
ZHU Wei	Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China
HU Jie	Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China
ZHAO Gang	Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China National Clinical Study Center for Radiology and Therapy, Shanghai 200032, China Shanghai Institute of Cardiovascular Diseases, Shanghai 200032, China
YANG Xiang-dong	Central Laboratory of Shanghai Institute of Cardiovascular Diseases, Shanghai 200032, China National Clinical Study Center for Radiology and Therapy, Shanghai 200032, China
DU Shi-suo	Department of Radiotherapy, Zhongshan Hospital, Fudan University, Shanghai 200032, China
LI Xiao-yu	Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai 200032, China
SHI Guo-ming	Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
CUI Jie	Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China National Clinical Study Center for Radiology and Therapy, Shanghai 200032, China Shanghai Institute of Cardiovascular Diseases, Shanghai 200032, China
WU Wei	Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai 200032, China
LI Jing	Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai 200032, China
ZHANG Chi	Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China National Clinical Study Center for Radiology and Therapy, Shanghai 200032, China Shanghai Institute of Cardiovascular Diseases, Shanghai 200032, China
WANG Cong	Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China National Clinical Study Center for Radiology and Therapy, Shanghai 200032, China Shanghai Institute of Cardiovascular Diseases, Shanghai 200032, China
LIU Rong-le	Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China National Clinical Study Center for Radiology and Therapy, Shanghai 200032, China Shanghai Institute of Cardiovascular Diseases, Shanghai 200032, China
LI Zheng	Department of Cardiac Ultrasound, Zhongshan Hospital, Fudan University, Shanghai 200032, China National Clinical Study Center for Radiology and Therapy, Shanghai 200032, China Shanghai Institute of Cardiovascular Diseases, Shanghai 200032, China Shanghai Institute of Imaging Medicine, Shanghai 200032, China
WANG Chun-hui	Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai 200032, China
CHENG Lei-lei	Department of Cardiac Ultrasound, Zhongshan Hospital, Fudan University, Shanghai 200032, China National Clinical Study Center for Radiology and Therapy, Shanghai 200032, China Shanghai Institute of Cardiovascular Diseases, Shanghai 200032, China Shanghai Institute of Imaging Medicine, Shanghai 200032, China	cheng.leilei@zs-hospital.sh.cn
GE Jun-bo	Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China National Clinical Study Center for Radiology and Therapy, Shanghai 200032, China Shanghai Institute of Cardiovascular Diseases, Shanghai 200032, China	ge.junbo@zs-hospital.sh.cn

Abstract:At present, immune checkpoint inhibitors (ICIs) have been used in the treatment of multiple malignant tumors, which benefit for tumor patients. However, the ICIs-associated myocarditis has brought new challenges clinically. In this recommendations paper, the key clinical issues, such as risk factors, diagnosis and differential diagnosis, clinical classification and treatment, monitoring of outcomes, and restart of treatment for ICIs-associated myocarditis, were highlighted, and the practical guidance and suggestions for the diagnosis and treatment of ICIs-associated myocarditis were proposed by reference to the relevant consensuses or guidelines and newly published evidence-based evidences in China and other countries in combination with clinical experience.

keywords:immune checkpoint inhibitors myocarditis cardiotoxicity immune-related adverse events

HTML View Full Text View/Add Comment Download reader